ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Val-Ganciclovir Prophylaxis Delays Onset of EBV Viremia in the First Year Post-Solid Organ Transplantation in High-Risk Patients

S. Albatati,1 A. Sharma,2 S. Gantt,1 K. Haubrich,1 A. Wright,1 T. Blydt-Hansen.1

1University of British Columbia, Vancouver, Canada
2University of Manitoba, Winnipeg, Canada.

Meeting: 2018 American Transplant Congress

Abstract number: D156

Keywords: Epstein-Barr virus (EBV), High-risk, Prophylaxis, Viral therapy

Session Information

Session Name: Poster Session D: Kidney Infectious

Session Type: Poster Session

Date: Tuesday, June 5, 2018

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Introduction: Donor-derived primary Epstein-Barr virus (EBV) infection poses serious risks to EBV naïve children post-solid organ transplantation, including development of EBV-related PTLD. Currently, there is no consensus on the utility of antiviral prophylaxis. We examined the association between Val-ganciclovir prophylaxis (VAL) and onset of EBV viremia in the first six months after transplant, when immunosuppressant exposure is highest.

METHODS: Single center, retrospective study of EBV naïve pediatric heart and renal transplant recipients (n=44) with an EBV positive donor from January 1996- April 2017. Treatment exposure in patients who received VAL for CMV risk (n=28) was tested for association with viremia-free survival in the first 6 months post-transplantation. Survival models tested early exposure (minimum of 30 days) and duration of prophylaxis, with bivariate adjustment for other baseline confounders.

RESULTS: The cohort included 24 (55%) males, 2 (5%) heart transplants, aged 11.8 ± 6.25 years at transplant. 22 (50%) developed viremia in the first-year post-transplantation. Mean time-to-viremia (TTV) of 144 vs. 58 days for VAL, no-VAL respectively. VAL was associated with freedom from viremia (p=0.008) in the first 6 months Only 3 out of 22 viremic patients developed viremia while on VAL, and those with delayed viremia had onset 39 ± 23 days after stopping VAL. Duration of VAL was associated with TTV (Cox, HR 0.986, 95% CI 0.977-0.994, p<0.001), with each additional day of VAL associated with 1.4% increase in viremia-free survival. Bivariate modelling of VAL with other baseline risk factors did not identify any other independent risk factors. Accelerated failure time modelling confirms the protective effect of VAL in the first year post-transplant, extending TTV by a factor of 1.0095 (p<0.001) for each day on treatment.

CONCULSION: VAL prophylaxis is associated with delayed onset of EBV viremia, with incremental benefit from each additional day of treatment.

CITATION INFORMATION: Albatati S., Sharma A., Gantt S., Haubrich K., Wright A., Blydt-Hansen T. Val-Ganciclovir Prophylaxis Delays Onset of EBV Viremia in the First Year Post-Solid Organ Transplantation in High-Risk Patients Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Albatati S, Sharma A, Gantt S, Haubrich K, Wright A, Blydt-Hansen T. Val-Ganciclovir Prophylaxis Delays Onset of EBV Viremia in the First Year Post-Solid Organ Transplantation in High-Risk Patients [abstract]. https://atcmeetingabstracts.com/abstract/val-ganciclovir-prophylaxis-delays-onset-of-ebv-viremia-in-the-first-year-post-solid-organ-transplantation-in-high-risk-patients/. Accessed March 26, 2023.

« Back to 2018 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2023 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences